Ergomed Aktie - WKN: A117XM

Ergomed’s CFO Richard Barfield at the Proactive One2One Investor Forum:
https://www.youtube.com/watch?v=KGfO_FEasaQ
 

In this interview, Ergomed's CFO Richard Barfield runs through:

- The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
- How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
- Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
- An overview of Ergomed’s M&A strategy.
- The outlook towards upcoming newsflow.

Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.

https://www.youtube.com/watch?v=rAu9IWSKsOc  

Der Kurs steigt und steigt - wann sehen wir die 16-18 Euro Marke bei ERGOMED ?  

Jupiter Fund Management Plc - Citibank  steigt bei ERGOMED ein:
https://www.investegate.co.uk/ergomed-plc--ergo-/...010211726378417C/  

Latest Ergomed case study on a retrospective, cross-sectional, non-interventional epidemiological study in non-small cell lung cancers (NSCLC) with 6 study sites across 5 countries in the MENA region. This was the first non-interventional epidemiology study in NSCLC conducted in different countries, resulting in, for the first time, generation of important data on the prevalence of anaplastic lymphoma kinase (ALK) gene rearrangement in the Middle East and North Africa.

Read the complete case study here: https://lnkd.in/ezGyzj9
 

Sharecast News | 06 Dec, 2020

The Mail on Sunday's Midas column recommended readers 'buy' shares of pharmacovigilance specialist Ergomed.

https://www.sharecast.com/amp/news/...d-johnson-matthey--7738206.html
 

Ergomed Acquires MedSource
https://www.contractpharma.com/contents/...rgomed-acquires-medsource/  

2020 Trading Update
https://www.ergomedplc.com/ergomed-2020-trading-update/

und Kursziel angehoben
https://www.edisongroup.com/publication/...o-strengthened-in-us/28692
 

Ergomed reveal 'another good year, with strong top line growth and overall financial performance'
https://www.proactiveinvestors.co.uk/companies/...rmance--939602.html  

releasing the results for the Full Year of 2020. We will be hosting a presentation for analysts and investors at 9am GMT. Visit the investor site to access the presentation, which will be uploaded today.

https://www.ergomedplc.com/investor-relations/...s-and-presentations/  

Kursziel angehoben auf 1400p / 16,20€

https://www.edisongroup.com/publication/...undamentals-for-2021/29121  

Ergomed highlight 'year of strong delivery' both financially and strategically
https://www.youtube.com/watch?v=drO9MrxG9Kg  

Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Ergomed made exceptional progress in delivering its strategy in 2020, despite the challenges of the COVID-19 pandemic. The resilience and robustness of our global services business was demonstrated by our continued strong organic growth whilst completing key strategic acquisitions in the US in both our pharmacovigilance and CRO businesses. We have started 2021 in a strong position, focused on our vision to achieve global leadership in specialised pharmaceutical services addressing unmet medical needs and patient safety.”

https://www.pharmiweb.com/press-release/...ear-ended-31-december-2020  

Ergomed (ERGO) - Richard Barfield, CFO
https://www.youtube.com/watch?v=EZWCR4ksK5o  

.... es ist wieder so schön ruhig -  der nächste Deal steht bestimmt schon in den Startlöchern ;)  

Ergomeds  “Pharmacovigilance Impact Series” continues!
The Impact of Covid-19 on Pharmacovigilance

In this webinar, our expert speakers, Dr. Marcela Fialova and Dr. Hyankova Jana, will give insight into Covid’s impact on the EU and the UK pharmacovigilance processes, highlighting the challenges that the Pharmaceutical Industry has had to face and how they adapted.

https://www.bigmarker.com/...on-Pharmacovigilance?show_live_page=true  

MedSource and PSR Orphan Experts rebrand to Ergomed
...successful integration of both PSR Orphan Experts and MedSource we will be aligning all our CRO businesses under the Ergomed name.
https://www.ergomedplc.com/...-psr-orphan-experts-rebrand-to-ergomed/  

Europe Drug Safety Solutions and Pharmacovigilance Market​​​​​​​ 2020 Demand, Growth, Technology Trends, Key Findings And Forecasts By 2027

https://ksusentinel.com/2021/04/14/...ndings-and-forecasts-by-2027-r/  

Das nächste Double Bottom ist gebaut - die ängstlichen sind draußen - wer hier verkauft, verbaut sich die Zukunftsaussichten in einem Wachstumsmarkt in dem nur wenige Player aktiv sind.  

ERGOMED - mit dem nächsten Deal steht der nächste Sprung bevor!


The Impact of Covid-19 on Pharmacovigilance

As a part of the Ergomed plc group, PrimeVigilance is the global leader in pharmacovigilance and specialized multi-lingual medical information services in 100+ countries.

https://www.bigmarker.com/...on-Pharmacovigilance?show_live_page=true

Hosted By BioAlliance Video Network  

Wachstum! -Ergomed opens PrimeVigilance business in Japan

The Japanese pharmaceutical market is the fourth-largest in the world after the US, the EU and China

“With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region.

“Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist."

https://www.proactiveinvestors.co.uk/companies/...n-japan-947566.html  

https://www.ergomedplc.com/ergomed-expands-operations-in-japan/  

https://yurui.jp/...%A7%E3%81%AE%E4%BA%8B%E6%A5%AD%E6%8B%A1%E5%A4%A7/  

Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises.
https://www.investegate.co.uk/ergomed-plc--ergo-/...104290700119928W/  

Mark Enyedy Appointed to Board as Non-Executive Director

Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.


Prior to ImmunoGen, Mr Enyedy served in various executive capacities at [b]Shire[/b] plc, including as [b]Executive Vice President and Head of Corporate Development[/b], a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at [b]Genzyme[/b] Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.

https://www.investegate.co.uk/ergomed-plc--ergo-/...105100700089974X/